PULSE BIOSCIENCES INC

Pulse Biosciences shares climbed to a new all-time high of $48.92; market capitalization rose to $3.46 billion. Performance stands at +186.1% over one year and +248% year-to-date, but InvestingPro rates the stock as overvalued and the RSI as overbought. Q2 results missed estimates with an adjusted loss of $0.36 per share and revenue of $400,000; the company reports progress in clinical trials. Analysts such as Needham and Canaccord confirmed buy ratings or raised price targets following clinical and regulatory progress. » More on de.investing.com

Pulse Biosciences shares rose to a new all-time high of 46.03 USD and are trading near their 52-week high. Technical indicators point to an overbought condition, while the stock has gained about 163.8% over one year and 216% year-to-date, giving it a market capitalization of roughly 3.24 billion USD. Quarterly results showed an adjusted loss of 0.36 USD per share and revenue of 400,000 USD, missing estimates. Despite the numbers, sentiment remains positive due to faster patient enrollment in the approval study and progress in ablation programs; Canaccord raised its price target to 43 USD and reiterated a "Buy" rating. » More on de.investing.com

Pulse Biosciences gained 117% after a productive quarter and CEO comments about strong momentum in the cardiac catheter program. Canaccord raised its price target to $43. The company announced a partnership for thyroid nodule studies, has recruited more than half of the patients in the approval‑relevant NANOPULSE‑AF study and expects to complete enrollment in early Q4; the nPulse technology is also planned to be evaluated for the treatment of atrial fibrillation. » More on deraktionaer.de